See more : Skymark Airlines Inc. (9204.T) Income Statement Analysis – Financial Results
Complete financial analysis of Evotec SE (EVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evotec SE, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Ningbo Zhongbai Co., Ltd. (600857.SS) Income Statement Analysis – Financial Results
- PT Hanson International Tbk (MYRX.JK) Income Statement Analysis – Financial Results
- Westhaven Gold Corp. (WHN.V) Income Statement Analysis – Financial Results
- ReYuu Japan Inc. (9425.T) Income Statement Analysis – Financial Results
- Carbios SAS (ALCRB.PA) Income Statement Analysis – Financial Results
Evotec SE (EVO)
About Evotec SE
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 781.43M | 751.45M | 618.03M | 500.92M | 446.44M | 375.41M | 257.63M | 164.51M | 127.68M | 89.50M | 85.94M | 87.27M | 80.13M | 55.26M | 42.68M | 39.61M | 32.89M | 67.35M | 64.12M | 1.94M | 3.57M | 0.00 | 0.00 |
| Cost of Revenue | 606.38M | 577.38M | 466.49M | 375.18M | 313.55M | 263.39M | 175.06M | 105.95M | 89.69M | 60.12M | 54.72M | 56.24M | 45.14M | 30.92M | 24.26M | 21.98M | 24.86M | 44.40M | 42.99M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 175.05M | 174.07M | 151.54M | 125.74M | 132.89M | 112.02M | 82.57M | 58.55M | 37.99M | 29.38M | 31.22M | 31.02M | 34.99M | 24.35M | 18.42M | 17.64M | 8.02M | 22.95M | 21.13M | 1.94M | 3.57M | 0.00 | 0.00 |
| Gross Profit Ratio | 22.40% | 23.16% | 24.52% | 25.10% | 29.77% | 29.84% | 32.05% | 35.59% | 29.75% | 32.83% | 36.33% | 35.55% | 43.66% | 44.06% | 43.16% | 44.52% | 24.40% | 34.08% | 32.95% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 57.52M | 76.64M | 72.20M | 63.95M | 58.43M | 35.62M | 17.61M | 18.11M | 18.34M | 12.40M | 9.66M | 8.34M | 8.44M | 6.12M | 20.95M | 42.54M | 36.94M | 30.31M | 9.30M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 152.74M | 142.70M | 96.02M | 77.24M | 66.55M | 57.01M | 42.38M | 27.01M | 25.17M | 17.99M | 16.60M | 16.30M | 15.76M | 15.96M | 16.70M | 19.95M | 17.81M | 18.58M | 15.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 16.87M | 13.49M | 9.42M | 9.50M | 9.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 169.61M | 156.19M | 105.45M | 77.24M | 66.55M | 57.01M | 42.38M | 27.01M | 25.17M | 17.99M | 16.60M | 16.30M | 15.76M | 15.96M | 16.70M | 19.95M | 17.81M | 18.58M | 15.54M | 6.10M | 5.27M | 5.02M | 4.27M |
| Other Expenses | -4.57M | -79.62M | -67.78M | -67.21M | -66.60M | 257.00K | -209.00K | 4.00K | 263.00K | 39.00K | 16.00K | 171.00K | 1.49M | 1.80M | -3.29M | -11.87M | 149.00K | 274.00K | 614.00K | -38.30M | -41.99M | -28.93M | -17.01M |
| Operating Expenses | 222.56M | 153.22M | 109.86M | 73.98M | 58.38M | 49.22M | 43.89M | 21.81M | 40.52M | 27.24M | 27.05M | 30.72M | 30.65M | 27.17M | 38.03M | 63.13M | 57.24M | 53.75M | 36.26M | -32.20M | -36.72M | -23.91M | -12.74M |
| Cost & Expenses | 828.93M | 730.60M | 576.36M | 449.16M | 371.92M | 312.61M | 218.96M | 127.76M | 130.21M | 87.35M | 81.77M | 86.96M | 75.79M | 58.08M | 62.30M | 85.11M | 82.10M | 98.15M | 79.25M | -32.20M | -36.72M | -23.91M | -12.74M |
| Interest Income | 9.26M | 8.34M | 2.27M | 1.34M | 2.23M | 898.00K | 903.00K | 863.00K | 533.00K | 469.00K | 261.00K | 655.00K | 413.00K | 241.00K | 499.00K | 2.96M | 1.96M | 1.37M | 851.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 11.74M | 13.15M | 9.25M | 8.47M | 7.46M | 2.59M | 1.26M | 1.52M | 1.73M | 1.62M | 1.87M | 1.86M | 1.86M | 866.00K | 433.00K | 839.00K | 483.00K | 671.00K | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 92.98M | 81.66M | 67.61M | 56.06M | 48.81M | 31.29M | 20.77M | 11.89M | 11.94M | 8.54M | 9.17M | 8.82M | 6.61M | 5.51M | 4.78M | 5.13M | 8.94M | 9.61M | 16.40M | 2.14M | 2.03M | 0.00 | 0.00 |
| EBITDA | 24.13M | -86.08M | 298.41M | 75.50M | 86.77M | 105.88M | 35.50M | 45.57M | 24.93M | 5.00M | -14.07M | 4.51M | 13.90M | 9.49M | -39.61M | -70.01M | -36.08M | -22.15M | -18.44M | -67.56M | -31.12M | -23.91M | -12.74M |
| EBITDA Ratio | 3.09% | 12.53% | 15.36% | 19.76% | 27.25% | 25.25% | 22.65% | 29.87% | 7.99% | 12.50% | 15.84% | 11.40% | 17.82% | 16.76% | -40.03% | -125.03% | -109.71% | -29.29% | -0.94% | -1,452.23% | -870.96% | 0.00% | 0.00% |
| Operating Income | -47.51M | 12.50M | 27.32M | 48.52M | 62.59M | 77.46M | 37.50M | 31.34M | 11.64M | -6.38M | -21.35M | -3.20M | 5.21M | 1.72M | -42.30M | -73.21M | -58.12M | -36.76M | -32.97M | -30.26M | -33.15M | -23.91M | -12.74M |
| Operating Income Ratio | -6.08% | 1.66% | 4.42% | 9.69% | 14.02% | 20.63% | 14.55% | 19.05% | 9.12% | -7.13% | -24.84% | -3.67% | 6.50% | 3.10% | -99.10% | -184.81% | -176.72% | -54.58% | -51.42% | -1,562.82% | -927.80% | 0.00% | 0.00% |
| Total Other Income/Expenses | -33.09M | -174.81M | 195.98M | -22.72M | -6.03M | -5.46M | -11.16M | 1.61M | 851.00K | 1.22M | -2.30M | -6.55M | 49.00K | 2.15M | -21.16M | -28.20M | 1.37M | -1.46M | -20.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -80.59M | -153.96M | 236.98M | 25.81M | 56.56M | 72.00M | 26.33M | 32.95M | 12.49M | -5.16M | -23.65M | -5.01M | 5.26M | 3.87M | -44.82M | -75.97M | -54.41M | -35.98M | -35.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -10.31% | -20.49% | 38.34% | 5.15% | 12.67% | 19.18% | 10.22% | 20.03% | 9.78% | -5.76% | -27.52% | -5.75% | 6.56% | 7.00% | -105.00% | -191.78% | -165.44% | -53.41% | -55.42% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.32M | 21.70M | 21.47M | 19.56M | 19.33M | -12.06M | 2.33M | 6.11M | -4.03M | 1.82M | 1.79M | -7.49M | -1.40M | 882.00K | 678.00K | 2.32M | -6.35M | 320.00K | -4.53M | -798.91K | 96.08K | 23.90M | 12.77M |
| Net Income | -83.91M | -175.66M | 215.51M | 6.28M | 38.16M | 84.17M | 24.26M | 27.53M | 16.52M | -6.98M | -25.43M | 2.48M | 6.75M | 3.26M | -45.50M | -78.29M | -11.16M | -32.47M | -33.58M | -29.46M | -33.25M | -23.90M | -12.77M |
| Net Income Ratio | -10.74% | -23.38% | 34.87% | 1.25% | 8.55% | 22.42% | 9.42% | 16.73% | 12.94% | -7.80% | -29.59% | 2.84% | 8.42% | 5.90% | -106.59% | -197.63% | -33.92% | -48.21% | -52.38% | -1,521.56% | -930.49% | 0.00% | 0.00% |
| EPS | -0.47 | -0.99 | 1.30 | 0.04 | 0.25 | 0.57 | 0.16 | 0.20 | 0.13 | -0.05 | -0.21 | 0.02 | 0.06 | 0.03 | -0.43 | -0.82 | -0.16 | -0.49 | -0.65 | -1.36 | -37.01 | -39.97 | -40.78 |
| EPS Diluted | -0.47 | -0.99 | 1.30 | 0.04 | 0.25 | 0.57 | 0.16 | 0.20 | 0.12 | -0.05 | -0.21 | 0.02 | 0.06 | 0.03 | -0.43 | -0.82 | -0.16 | -0.49 | -0.65 | -1.36 | -37.01 | -39.97 | -40.78 |
| Weighted Avg Shares Out | 176.92M | 176.67M | 166.41M | 153.75M | 149.73M | 147.48M | 145.01M | 132.51M | 131.68M | 131.29M | 121.22M | 117.30M | 116.02M | 109.01M | 106.85M | 95.20M | 71.83M | 66.36M | 51.99M | 21.71M | 898.27K | 597.93K | 313.09K |
| Weighted Avg Shares Out (Dil) | 176.92M | 176.70M | 166.41M | 153.75M | 149.73M | 147.48M | 145.01M | 132.51M | 137.63M | 131.29M | 121.22M | 117.30M | 116.02M | 109.01M | 106.85M | 95.20M | 71.83M | 66.36M | 51.99M | 21.71M | 898.27K | 597.93K | 313.09K |
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Germany-based Evotec SE EVO is trading on Monday after a report that suggests the company is a takeover target.
Evotec SE (EVO) Q3 2024 Earnings Call Transcript
Evotec SE (NASDAQ:EVO ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Laetitia Rouxel - Chief Financial Officer Cord Dohrmann - Chief...
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships Successful...
Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners Transaction aligns with Evotec's strategic optimization efforts, concentrating resources on key growth drivers New ownership committed to maintaining and growing the business HAMBURG, GERMANY / ACCESSWIRE /...
Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024
HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024. The Company is going to hold a...
Evotec and Bristol Myers Squibb Expand Proteomics Partnership
Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value HAMBURG, GERMANY /...
Kia Gwangmyeong EVO Plant Opens to Significantly Expand EV Production
Kia celebrates the completion of Hyundai Motor Group's first dedicated EV manufacturing facility Kia Gwangmyeong EVO Plant, located at Kia Autoland Gwangmyeong, to mass-produce Kia EV3 and EV4 models The new facility to have production capacity of 150,000 units per...
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
On Thursday, Evotec SE EVO entered a technology development partnership with Novo Nordisk A/S NVO in cell therapy.
Evotec and Novo Nordisk forge technology development partnership
German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, the company said on Thursday.
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced...
Source: https://incomestatements.info
Category: Stock Reports